title: β-Blocker therapy in heart failure with preserved ejection fraction: Importance of dose and duration.
abstract: Heart failure is currently a social welfare and economic burden. In particular, the prevalence of heart failure with preserved ejection fraction (HFpEF) has increased and is currently equal to that of heart failure with reduced ejection fraction (HFrEF). Prognosis of HFrEF has improved in the past two decades, because many clinical studies have revealed the effectiveness of several pharmacological and non-pharmacological interventions for HFrEF patients, one of which is β-blockers. In contrast, there is no established therapeutic intervention to provide beneficial effects on HFpEF, and mortality and morbidity of HFpEF are currently as poor as those of HFrEF. This review will discuss β-blockers from a standpoint of therapeutic strategy for HFpEF.
authors.affiliation: Division of Cardiovascular Medicine, Endocrinology and Metabolism, Department of Molecular Medicine and Therapeutics, Faculty of Medicine, Tottori University, Yonago, Japan. Electronic address: ykazuhiro@med.tottori-u.ac.jp.
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Yamamoto
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006333:Heart Failure / Q000188:drug therapy*; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D012084:Renin-Angiotensin System / Q000187:drug effects; D013318:Stroke Volume
chemical_list: D000319:Adrenergic beta-Antagonists
keywords: Diastole; Heart failure; β-Blocker